The IBC panel included the two well-established lines: SUM149 (activated ErbB1, ER/PR negative, ErbB2 low) and SUM190 (ErbB2 overexpressing, ER/PR negative), both of which were originally derived from primary IBC tumours, SUM44 (ErbB2 low, ER/PR positive) cell line derived from the pleural effusion of a patient with luminal breast cancer (Forozan et al, 1999), and two isogenic clonal derivatives of the SUM149 and SUM190 that have gained resistance to ErbB1/2 targeting agents such as lapatinib termed rSUM149 and rSUM190 (Aird et al, 2010). This evidence concerns the gene EGFR and inflammatory breast carcinoma.